Literature DB >> 23859341

Mitochondrial pathophysiology in Friedreich's ataxia.

Pilar González-Cabo1, Francesc Palau.   

Abstract

Neurological examination indicates that Friedreich's ataxia corresponds to a mixed sensory and cerebellar ataxia, which affects the proprioceptive pathways. Neuropathology and pathophysiology of Friedreich's ataxia involves the peripheral sensory nerves, dorsal root ganglia, posterior columns, the spinocerebellar, and corticospinal tracts of the spinal cord, gracile and cuneate nuclei, dorsal nuclei of Clarke, and the dentate nucleus. Involvement of the myocardium and pancreatic islets of Langerhans indicates that it is also a systemic disease. The pathophysiology of the disease is the consequence of frataxin deficiency in the mitochondria and cells. Some of the biological consequences are currently recognized such as the effects on iron-sulfur cluster biogenesis or the oxidative status, but others deserve to be studied in depth. Among physiological aspects of mitochondria that have been associated with neurodegeneration and may be interesting to investigate in Friedreich's ataxia we can include mitochondrial dynamics and movement, communication with other organelles especially the endoplasmic reticulum, calcium homeostasis, apoptosis, and mitochondrial biogenesis and quality control. Changes in the mitochondrial physiology and transport in peripheral and central axons and mitochondrial metabolic functions such as bioenergetics and energy delivery in the synapses are also relevant functions to be considered. Thus, to understand the general pathophysiology of the disease and fundamental pathogenic mechanisms such as dying-back axonopathy, and determine molecular, cellular and tissue therapeutic targets, we need to discover the effect of frataxin depletion on mitochondrial properties and on specific cell susceptibility in the nervous system and other affected organs.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  Friedreich's ataxia; dying-back axonopathy; frataxin deficiency; mitochondria; neural pathophysiology

Mesh:

Substances:

Year:  2013        PMID: 23859341     DOI: 10.1111/jnc.12303

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  32 in total

1.  Epigenetic therapy for Friedreich ataxia.

Authors:  Elisabetta Soragni; Wenyan Miao; Marco Iudicello; David Jacoby; Stefania De Mercanti; Marinella Clerico; Filomena Longo; Antonio Piga; Sherman Ku; Erica Campau; Jintang Du; Pablo Penalver; Myriam Rai; Joseph C Madara; Kristopher Nazor; Melinda O'Connor; Anton Maximov; Jeanne F Loring; Massimo Pandolfo; Luca Durelli; Joel M Gottesfeld; James R Rusche
Journal:  Ann Neurol       Date:  2014-09-16       Impact factor: 10.422

2.  Frataxin deficiency impairs mitochondrial biogenesis in cells, mice and humans.

Authors:  Mittal J Jasoliya; Marissa Z McMackin; Chelsea K Henderson; Susan L Perlman; Gino A Cortopassi
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

Review 3.  Modeling mitochondrial function and its role in disease.

Authors:  M Saleet Jafri; Rashmi Kumar
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

Review 4.  Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.

Authors:  Dmitriy M Niyazov; Stephan G Kahler; Richard E Frye
Journal:  Mol Syndromol       Date:  2016-06-03

5.  Inducible and reversible phenotypes in a novel mouse model of Friedreich's Ataxia.

Authors:  Vijayendran Chandran; Kun Gao; Vivek Swarup; Revital Versano; Hongmei Dong; Maria C Jordan; Daniel H Geschwind
Journal:  Elife       Date:  2017-12-19       Impact factor: 8.140

6.  Calpain-Inhibitors Protect Frataxin-Deficient Dorsal Root Ganglia Neurons from Loss of Mitochondrial Na+/Ca2+ Exchanger, NCLX, and Apoptosis.

Authors:  Elena Britti; Fabien Delaspre; Jordi Tamarit; Joaquim Ros
Journal:  Neurochem Res       Date:  2020-04-06       Impact factor: 3.996

Review 7.  Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.

Authors:  Shao-Hua Yang; Wenjun Li; Nathalie Sumien; Michael Forster; James W Simpkins; Ran Liu
Journal:  Prog Neurobiol       Date:  2015-11-18       Impact factor: 11.685

8.  Metabolism-Associated Markers and Childhood Autism Rating Scales (CARS) as a Measure of Autism Severity.

Authors:  Afaf El-Ansary; Geir Bjørklund; Asma M Khemakhem; Laila Al-Ayadhi; Salvatore Chirumbolo; Abir Ben Bacha
Journal:  J Mol Neurosci       Date:  2018-06-22       Impact factor: 3.444

Review 9.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Authors:  Maryka Quik; Danhui Zhang; Xiomara A Perez; Tanuja Bordia
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

Review 10.  Friedreich's ataxia: clinical features, pathogenesis and management.

Authors:  A Cook; P Giunti
Journal:  Br Med Bull       Date:  2017-12-01       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.